ASX:PABINVESTOR PRESENTATION · OCTOBER 2026B rid g in g G ap s in T h erap eu tic C areDeveloping the potential first treatment for delirium approved broadlyIn the clinicKnown moleculeFDA 505(b)(2) pathwayGlobal unmet needpatrys.comDisclaimerPatrys Limited...
Investor Presentation
Filed with ASX · · 17 pages · English
Release
Earlier from Patrys
- Investor Webinar
- Appendix 4E Variance Report
- First Participants Dosed in RLS-2202 Phase 1A Clinical Trial
- PAB Establishes Clinical Advisory Committee
- Ethics Approval Secured for Phase 1A Clinical Trial
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys